New drug cocktail aims to spare transplant patients from chemo

This study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ or stem cell transplant. The goal is to see if this combo is safe and effective enough to replace standard chemotherapy, which has harsh side effects. The trial will enroll 12 people and also explore how the tumor environment and a common virus might predict outcomes.